MBX Biosciences, Inc. (MBX) vs NewAmsterdam Pharma Company N.V. (NAMS)
MBX Biosciences, Inc. and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. MBX Biosciences, Inc. and NewAmsterdam Pharma Company N.V. are of similar size ($2.7B and $2.7B). MBX Biosciences, Inc. has the higher net margin (0.00% vs −3,644.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, MBX Biosciences, Inc. leads on 9 and NewAmsterdam Pharma Company N.V. on 2.
Valuation
Profitability
| Metric | MBX | NAMS | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 65.16% |
| Operating margin | 0.00% | (3,432.20%) | 0.00% |
| Net margin | 0.00% | (3,644.21%) | 0.00% |
| Free cash flow margin | 0.00% | (2,018.28%) | 0.00% |
| Return on equity | (33.17%) | (36.81%) | (57.72%) |
| Return on assets | (31.25%) | (34.16%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack